ReviewFrontiers in oncology2021
Clinical Application of
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.BMC urology · 2023Pooled it
- [Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future].Pathologie (Heidelberg, Germany) · 2026Review
- TERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population.Cancer cell international · 2026Article
- Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers.Scientific reports · 2025Article
- Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.Journal of clinical medicine · 2024Review
- Article
- Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors.Current issues in molecular biology · 2024Article
- Upper tract urothelial carcinoma accompanied by hyperthermia: A case report.Urology case reports · 2024Article
- Pan-cancer experimental characteristic of human transcriptional patterns connected with telomerase reverse transcriptase (Frontiers in genetics · 2024Article
- A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial Carcinoma: A Case Report and Review of the Literature.International journal of surgical pathology · 2023Review
- Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.Diagnostic pathology · 2023Article
- Urinary Analysis ofThe Journal of urology · 2023Article
- Nano pom-poms prepared exosomes enable highly specific cancer biomarker detection.Communications biology · 2022Article
- Review
- Urinary Exosomal Long Noncoding RNA TERC as a Noninvasive Diagnostic and Prognostic Biomarker for Bladder Urothelial Carcinoma.Journal of immunology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma (UC) is a common urological malignancy with a high rate of disease recurrence. Telomerase activity, a hallmark of cancer characterized by overcoming the replicative senescence, is upregulated in over 90% of patients with UC. Somatic mutations in the promoter region of telomerase reverse transcriptase (TERT) are frequently detected in UC, and drive telomerase activity. Recent studies have demonstrated a strong association between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.